Patents by Inventor Remko Alexander BAKKER

Remko Alexander BAKKER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-TRKB ANTIBODIES
    Publication number: 20240101689
    Abstract: The present invention relates to novel agonistic anti-TrkB antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Application
    Filed: November 28, 2023
    Publication date: March 28, 2024
    Inventors: Rolf HERRMANN, Remko Alexander BAKKER, Sebastian BANDHOLTZ, Peter Michael BENZ, Michael DZIEGELEWSKI, Lore Katharina FLORIN, Cynthia Hess KENNY, Sarah Kathleen LOW, Holger ROSENBROCK, Sanjaya SINGH, Heiko Friedrich STAHL, Sathyadevi VENKATARAMANI, Vladimir H. VOYNOV, Haiguang XIAO
  • Anti-TrkB antibodies
    Patent number: 11866501
    Abstract: The present invention relates to novel agonistic anti-TrkB antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Grant
    Filed: August 26, 2020
    Date of Patent: January 9, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Rolf Herrmann, Remko Alexander Bakker, Sebastian Bandholtz, Peter Michael Benz, Michael Dziegelewski, Lore Katharina Florin, Cynthia Hess Kenny, Sarah Kathleen Low, Holger Rosenbrock, Sanjaya Singh, Heiko Friedrich Stahl, Sathyadevi Venkataramani, Vladimir H. Voynov, Haiguang Xiao
  • ANTI-SEMA3A ANTIBODIES AND THEIR USES FOR TREATING A THROMBOTIC DISEASE OF THE RETINA
    Publication number: 20220127344
    Abstract: The invention relates to the use of antibodies and antibody that target semaphorin 3A (Sema3A), and fragments thereof, and their use for treating thrombotic diseases of the retina comprising.
    Type: Application
    Filed: October 21, 2021
    Publication date: April 28, 2022
    Inventors: Leo THOMAS, Remko Alexander BAKKER
  • AGONISTIC TRKB BINDING MOLECULES FOR THE TREATMENT OF EYE DISEASES
    Publication number: 20220119536
    Abstract: The invention relates to agonistic TrkB binding molecules, methods for improving agonistic TrkB binders, their use in medicine, pharmaceutical compositions comprising the same, and methods of using the same as agents for treatment and/or prevention of diseases of the eye.
    Type: Application
    Filed: October 20, 2021
    Publication date: April 21, 2022
    Inventors: Peter Michael BENZ, Remko Alexander BAKKER, Holger FUCHS, Fei HAN, Sandeep KUMAR, Sarah LOW, Justin M. SCHEER, Leo THOMAS
  • BISPECIFIC ANTI-VEGF AND ANTI-TRKB BINDING MOLECULES FOR THE TREATMENT OF EYE DISEASES
    Publication number: 20220119535
    Abstract: This invention relates to binding molecules that bind specifically Vascular Endothelial Growth Factor (VEGF) and Tropomyosin receptor kinase B (TrkB) and their use in medicine, pharmaceutical compositions comprising the same, and methods of using the same as agents for treatment and/or prevention of diseases of the eye.
    Type: Application
    Filed: October 20, 2021
    Publication date: April 21, 2022
    Inventors: Peter Michael BENZ, Remko Alexander BAKKER, Holger FUCHS, Fei HAN, Sandeep KUMAR, Sarah LOW, Justin M. SCHEER, Leo THOMAS
  • ANTI-TRKB ANTIBODIES
    Publication number: 20200399378
    Abstract: The present invention relates to novel agonistic anti-TrkB antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Application
    Filed: August 26, 2020
    Publication date: December 24, 2020
    Inventors: Rolf HERRMANN, Remko Alexander BAKKER, Sebastian BANDHOLTZ, Peter Michael BENZ, Michael DZIEGELEWSKI, Lore Katharina FLORIN, Cynthia Hess KENNY, Sarah Kathleen LOW, Holger ROSENBROCK, Sanjaya SINGH, Heiko Friedrich STAHL, Sathyadevi VENKATARAMANI, Vladimir H. VOYNOV, Haiguang XIAO
  • Anti-TrkB antibodies
    Patent number: 10793634
    Abstract: The present invention relates to novel agonistic anti-TrkB antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: October 6, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Rolf Herrmann, Remko Alexander Bakker, Sebastian Bandholtz, Peter Michael Benz, Michael Dziegelewski, Lore Florin, Cynthia Hess Kenny, Sarah Low, Holger Rosenbrock, Sanjaya Singh, Heiko Friedrich Stahl, Sathyadevi Venkataramani, Vladimir Voynov, Haiguang Xiao
  • Pharmaceutical composition and pharmaceutical dosage form comprising (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof
    Publication number: 20200188337
    Abstract: The present invention relates to pharmaceutical compositions comprising (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide having the following chemical structure or a pharmaceutically acceptable salt thereof as active pharmaceutical ingredient, particularly to pharmaceutical compositions comprising (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide hydrochloride, to pharmaceutical dosage forms, to their preparation, their use and methods for therapeutic treatment.
    Type: Application
    Filed: February 19, 2020
    Publication date: June 18, 2020
    Inventors: Kenji EGUSA, Takuma KATAYAMA, Kazutoshi YOKOYAMA, Remko Alexander BAKKER, Ngai Hang Victor CHONG, Joerg RIPPMANN
  • Pharmaceutical composition and pharmaceutical dosage form comprising (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof
    Patent number: 10603292
    Abstract: The present invention relates to pharmaceutical compositions comprising (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide having the following chemical structure or a pharmaceutically acceptable salt thereof as active pharmaceutical ingredient, particularly to pharmaceutical compositions comprising (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide hydrochloride, to pharmaceutical dosage forms, to their preparation, their use and methods for therapeutic treatment.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: March 31, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Kenji Egusa, Takuma Katayama, Kazutoshi Yokoyama, Remko Alexander Bakker, Ngai Hang Victor Chong, Joerg Rippmann
  • Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
    Patent number: 10501440
    Abstract: Disclosed are heteroarylcarboxamides of formula (I), and pharmaceutically acceptable salts thereof, wherein A, T, R1, R2 and R3 are as defined herein. Also disclosed are methods of using these compounds for the treatment of diseases which can be influenced by inhibition of plasma kallikrein.
    Type: Grant
    Filed: April 16, 2018
    Date of Patent: December 10, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Sara Frattini, Iain Lingard, Dieter Wolfgang Hamprecht, Remko Alexander Bakker, Matthias Eckhardt, Andreas Gollner, Joerg P. Hehn, Elke Langkopf, Holger Wagner, Bernd Wellenzohn, Dieter Wiedenmayer
  • ANTI-TRKB ANTIBODIES
    Publication number: 20180355046
    Abstract: The present invention relates to novel agonistic anti-TrkB antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Application
    Filed: June 7, 2018
    Publication date: December 13, 2018
    Inventors: Rolf Herrmann, Remko Alexander Bakker, Sebastian Bandholtz, Peter Michael Benz, Michael Dziegelewski, Lore Florin, Cynthia Hess Kenny, Sarah Low, Holger Rosenbrock, Sanjaya Singh, Heiko Friedrich Stahl, Sathyadevi Venkataramani, Vladimir Voynov, Haiguang Xiao
  • Pharmaceutical composition and pharmaceutical dosage form comprising (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof
    Publication number: 20180344672
    Abstract: The present invention relates to pharmaceutical compositions comprising (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide having the following chemical structure or a pharmaceutically acceptable salt thereof as active pharmaceutical ingredient, particularly to pharmaceutical compositions comprising (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide hydrochloride, to pharmaceutical dosage forms, to their preparation, their use and methods for therapeutic treatment.
    Type: Application
    Filed: May 30, 2018
    Publication date: December 6, 2018
    Inventors: Kenji EGUSA, Takuma KATAYAMA, Kazutoshi YOKOYAMA, Remko Alexander BAKKER, Ngai Hang Victor CHONG, Joerg RIPPMANN
  • Heteroarylcarboxamide Derivatives as Plasma Kallikrein Inhibitors
    Publication number: 20180305339
    Abstract: Disclosed are heteroarylcarboxamides of formula (I), and pharmaceutically acceptable salts thereof, wherein A, T, R1, R2 and R3 are as defined herein. Also disclosed are methods of using these compounds for the treatment of diseases which can be influenced by inhibition of plasma kallikrein.
    Type: Application
    Filed: April 16, 2018
    Publication date: October 25, 2018
    Inventors: Sara FRATTINI, Iain LINGARD, Dieter Wolfgang HAMPRECHT, Remko Alexander BAKKER, Matthias ECKHARDT, Andreas GOLLNER, Joerg P. HEHN, Elke LANGKOPF, Holger WAGNER, Bernd WELLENZOHN, Dieter WIEDENMAYER